Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Becoril-L is a combination cough syrup developed and marketed by Ind Blues Pharma. It is formulated for the symptomatic relief of productive (chesty) coughs associated with bronchopulmonary disorders such as bronchitis, bronchial asthma, and chronic obstructive pulmonary disease (COPD). The formulation typically combines a mucolytic agent (Ambroxol) to thin and loosen thick mucus, an expectorant (Guaifenesin) to reduce mucus stickiness and facilitate expectoration, and a bronchodilator (Levosalbutamol) to relax airway smooth muscle and improve breathing. It may also contain levocetirizine to alleviate concurrent allergic symptoms like runny nose and sneezing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Becoril-L.